Alto Neuroscience (ANRO) Short term Debt (2024 - 2026)

Alto Neuroscience has disclosed Short term Debt across 3 years of filings, most recently posting $2.1 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $2.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (changed N/A YoY), and the FY2025 annual result was $585000.0, changed N/A from the prior year.
• Short term Debt came in at $2.1 million for Q1 2026 at Alto Neuroscience, up from $585000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $3.5 million in Q3 2024 to a low of $585000.0 in Q4 2025.
• The 3-year median for Short term Debt is $2.1 million (2026), against an average of $1.9 million.